Hypoxia-activated nitroreductase and Deoxyribonucleic acid (DNA) (NTR/DNA)

Hypoxia-associated nitroreductase enzymes and DNA constitute a dual-component therapeutic target system primarily utilized in the development of hypoxia-activated prodrugs (HAPs) for oncology. In the oxygen-depleted microenvironment of solid tumors, specific enzymes such as cytochrome P450 oxidoreductase (POR) or exogenous bacterial nitroreductases catalyze the reduction of nitro-functional groups on prodrug molecules [1]. This bioreductive process converts relatively non-toxic precursors into highly reactive species, typically DNA-alkylating agents or topoisomerase inhibitors, which then bind to and damage the DNA within hypoxic tumor cells [2]. This damage leads to strand breaks, cross-linking, and subsequent apoptosis, specifically targeting the radioresistant and chemoresistant cell populations that drive tumor recurrence [3]. By exploiting the lack of oxygen, this target system allows for the selective destruction of malignant cells while minimizing damage to well-oxygenated healthy tissues [4]. Citations: [1] Wilson & Hay (2011) Nature Reviews Cancer; [2] Hunter et al. (2016) Molecular Cancer Therapeutics; [3] Duan et al. (2008) Journal of Medicinal Chemistry; [4] Phillips (2016) Journal of Medicinal Chemistry.

Other names

Hypoxia-activated prodrug targetBioreductive drug targetNTR-DNA axisNitroreductase-activated DNA alkylating system

Bioreductive activation where nitroreductase enzymes reduce a nitro-functional group on a prodrug under hypoxic conditions to release a cytotoxic DNA-damaging agent.